

12 February 2026

## Grant of Australian patent significantly strengthens TRP-8803's IP position and long-term competitive moat

- Australian patent relating to novel, precision-controlled method of administering psilocybin, psilocin and related forms to treat a range of pain disorders has been granted
- Protects the core IP underpinning TRP-8803 (IV-infused psilocin) through to 2042
- Patent claims granted provide extensive protection around the use of two-phase IV dosing, time to onset of desired treatment state, control of treatment duration, and EEG-monitoring for biomarker development
- Patent unlocks broad protection across psilocybin, psilocin and related chemical variants and a range of high-value conditions including anxiety, addictive and eating disorders, PTSD, and pain conditions

**Melbourne, Australia** – Entropy Neurodynamics Limited ('Entropy Neurodynamics', 'ENP' or the 'Company') (ASX: ENP), a clinical-stage biotechnology company, is pleased to announce the grant of its Australian patent covering the Company's novel, precision-controlled method of administering psilocybin, psilocin and related forms to treat a range of psychological and nociceptive pain disorders. Nociceptive pain is a type of chronic pain resulting from altered, heightened pain signaling in the central nervous system, rather than direct tissue damage or nerve injury. This patent underpins the Company's lead asset TRP-8803 (IV-infused psilocin) and provides long-dated IP protection through to 2042.

Specifically, the patent materially strengthens Entropy's competitive position by providing method-level protection over a clinically differentiated IV psychedelic treatment model. The claims cover the Company's proprietary two-phase dosing regimen – a loading dose followed by a controlled maintenance infusion – which delivers a reproducible, controllable pharmacokinetic profile, unique to the Company and fundamental to safety, efficacy and scalability. By targeting method protection, Entropy has created a high barrier to entry that cannot be replicated without infringement.

Importantly, the patent protects the Company's ability to rapidly stop treatment by ending the infusion. This control has significant safety, operational and commercial advantage not achievable with oral dosing. Further, any similar controllable IV approach would be difficult to develop without violating the patent.

Key elements protected under the patent include the rapid induction of the psychedelic state or therapeutic window, within a defined period of 5-30 minutes and controlled maintenance of drug levels over the treatment period. This delivers a clear advantage over oral dosing by enabling predictable onset, consistent exposure and clinician control. Importantly, this creates a strong competitive moat, as any IV approach seeking similar control and repeatability would be difficult to develop without infringing the claims.

The patent protects the use of EEG-based monitoring, enabling objective, real-time biomarker development, adding additional defensibility around safety, optimisation and clinical validation, while also supporting future regulatory and reimbursement initiatives.

For personal use only



Importantly, the patent provides broad protection across psilocybin, psilocin and related chemical variants, preventing design around attempts and coverage across multiple maintenance delivery routes, including IV, oral, transdermal, subcutaneous and intranasal, helping future-proof Entropy's asset base as new delivery technologies emerge.

Claims span multiple high-value neuropsychiatric indications, including fibromyalgia, PTSD, anxiety, addiction and eating disorders.

Collectively, these protections secure a defensible, scalable and indication-agnostic treatment platform, providing the Company with long-dated protection around how psychedelic therapies are delivered, monitored and controlled—key attributes that support Entropy's long-term commercial strategy.

Importantly, the inclusion of EEG-based monitoring strengthens the Company's position in the emerging field of precision psychiatry, supporting the development of objective, real-time biomarkers that may guide treatment selection, dosing optimisation and clinical validation. This aligns with the Company's broader strategy to integrate entropy-based biomarkers into future clinical programs.

Additional patent applications, which are based on the Company's recently granted claims are well advanced across other jurisdictions, including the USA. Entropy will provide further updates to the grant of these potential patents as developments materialise.

#### **Management commentary:**

**CEO, Mr Jason Carroll said:** *"This patent grant significantly strengthens Entropy's IP position and materially enhances the long-term value of TRP-8803. Importantly, we have secured protection not just around the molecule, but around the method of delivery — how the treatment is induced, controlled, monitored and stopped. That level of method-based protection creates an extensive barrier to entry that is extremely difficult for competitors to design around."*

*"Our two-phase IV model, with rapid onset, controlled maintenance and the ability to stop treatment on demand, delivers a differentiated clinical profile that is impossible to replicate with oral dosing. Securing protection through to 2042 provides long-dated exclusivity over this precision-controlled approach."*

*"Strategically, the breadth of coverage across compounds, dosing ranges, delivery routes and multiple high-value indications, supports a scalable, multi-indication platform. This positions Entropy favourably as we advance TRP-8803 through clinical development and engage with potential strategic partners focused on next-generation neuropsychiatric therapeutics."*

#### **Q&A:**

##### **What has Entropy Neurodynamics been granted a patent for?**

The patent protects a novel, precision-controlled method for administering psilocybin, psilocin and related forms using a two-phase IV infusion. It covers how the treatment is started, controlled, monitored and stopped.

##### **Why is this patent important?**

It provides long-dated protection through to 2042 for the core method behind TRP-8803, strengthening Entropy's competitive position as it advances clinical development.

##### **What is a "two-phase IV dosing" model?**

It is a method where treatment begins with a short loading dose to quickly bring a patient into the



therapeutic state, followed by a controlled maintenance infusion that keeps the experience stable and predictable.

### **How does this approach differ from oral psychedelic dosing?**

Oral dosing can be slow, unpredictable and difficult to control. The patented IV method allows clinicians to manage onset, depth and duration with far greater precision.

### **What does “ability to stop treatment” mean in practice?**

Because the treatment is delivered by IV infusion, clinicians can stop the psychedelic experience simply by stopping the infusion. This level of control is not possible with oral dosing.

### **Why is EEG monitoring included in the patent?**

The patent protects the use of EEG (a non-invasive brain-activity measurement) to help identify when a patient enters the therapeutic state. This supports the development of objective biomarkers for future precision-psychiatry applications.

### **Does the patent only apply to psilocin?**

No. It covers psilocybin, psilocin and related chemical variants, helping protect the method across a broader range of psychedelic compounds.

### **Which conditions does the patent relate to?**

The claims span multiple high-value neuropsychiatric indications, including anxiety, PTSD, addiction, eating disorders, fibromyalgia and other nociceptive pain disorders.

### **How does this patent support Entropy's long-term strategy?**

It secures protection around *how* psychedelic therapies are delivered and controlled, creating a defensible platform that supports multi-indication development and future partnering opportunities.

### **Does this patent apply outside Australia?**

This announcement relates specifically to the Australian patent grant. Corresponding applications in other jurisdictions remain under review, and outcomes will be announced as appropriate.

### **With this patent grant, is it difficult for other psychedelic compounds to be dosed through a two-phase infusion process?**

The patent protects Entropy's specific two-phase IV method — including how the loading dose is delivered, how the therapeutic state is induced within defined timeframes, how plasma levels are maintained and how EEG may be used to monitor the experience. Any party seeking to use a similar two-phase approach for psychedelic administration would need to ensure they do not infringe these protected method claims. While the patent does not prevent the development of other psychedelic compounds, it does create a meaningful barrier around this particular method of controlled IV delivery.

### **How does this patent benefit TRP-8803 specifically?**

TRP-8803 is built around the same precision-controlled IV method protected by the patent. The grant therefore strengthens the long-term value of the program by securing exclusivity around the dosing model, monitoring approach and treatment control features that differentiate TRP-8803 from traditional psychedelic therapies.

This announcement has been authorised by the Board of Entropy Neurodynamics

- ENDS -



---

#### INVESTOR & MEDIA CONTACT:

**Jason Carroll**

Chief Executive Officer  
Entropy Neurodynamics Limited  
[jcarroll@entropyneurodynamics.com](mailto:jcarroll@entropyneurodynamics.com)

**Henry Jordan**

Six Degrees Investor Relations  
+61 (0) 431 271 538  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)

***About Entropy Neurodynamics Limited***

*Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.*

*Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from each of these trials demonstrated the clinical benefits of psychedelic therapy and will be used to further enhance the development of TRP-8803.*

**Register for updates**

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done by:

- Go to [investor.automic.com.au](http://investor.automic.com.au)
- If you're an existing user, log in with your username and password
- If you're a new user, click 'register', select 'Entropy Neurodynamics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.
- Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'

***Risks associated with Psilocin***

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding.

Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimen used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

#### ***Forward-Looking Information***

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Entropy Neurodynamics as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Company's Replacement Prospectus available at [www.asx.com.au](http://www.asx.com.au) These factors are not intended to represent a complete list of the factors that could affect Entropy Neurodynamics; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For personal use only